Abstract
在恶性肿瘤患者中,血小板抑制症以前与疾病阶段,组织学型和生存有关。在本研究中,血小板增生的患病率和血小板计数提供的预后信息分析了患有原发性肺癌的大队患者。在诊断时,在1,115名连续验证原发性肺癌中回顾性记录预处理血小板计数。所有患者均考虑了组织学型,肿瘤,节点,转移(TNM)分类阶段和生存率。将肺癌患者血小板增生的患病率与良性肺病患者的一系列550连续患者进行比较。在269例手术切除患者中,在切除肿瘤后1-3个月后记录术后血小板计数。在随访期间,记录临床或尸检诊断的血栓栓塞发作。肺癌患者血小板增生(> 400×10(9)次血小板血小板的总体患病率为32%。与对照受试者相比,血小板减少症的频率显着高(32 vs 6%; P <0.0001)。血小板计数在TNM分类定义的亚组中有显着不同,患者比例> 400×10(9)个血小板的比例。在更先进的TNM阶段中最大的血小板(第I阶段和II 23%VS阶段III和IV 37)%; p <0.0001)。 Patients with thrombocytosis had a significantly poorer survival than patients with normal platelet counts (p < 0.0001). In a multivariate survival analysis (Cox model), thrombocytosis continued to correlate strongly with poor survival even when adjusted for histological type, sex, age, and TNM stage (p < 0.001). In surgically resected patients, the frequency of preoperative and postoperative thrombocytosis differed significantly (23.0 vs 8.9%; p < 0.0001). Survival rate was significantly reduced in patients with preoperative thrombocytosis (p = 0.005). Thrombocytosis was not associated with an increased incidence of thromboembolism. In conclusion, thrombocytosis is an independent prognostic factor of survival in patients with primary lung cancer. We suggest that platelet counts should be included in future multivariate analyses of survival in patients with lung cancer.